Internationally recognized expert joins to support the organization's commercialization strategy
MADISON, Wis., Sept. 25, 2025 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative platform to predict immunotherapy response, announced today that it has welcomed Jérôme Galon, Ph.D., to its Scientific Advisory Board (SAB). Based in France, Dr. Galon joins an expanding SAB composed of clinical and academic thought leaders who play a key role in the company's commercialization strategy focused on predicting response to immunotherapy using live tissue.
Galon is recognized as an award-winning visionary for decades in the global oncology community. He is Director of Research Exceptional Class, at INSERM; director and co-founder of the European Academy of Tumor Immunology (EATI); and former board director of the Society of Immunotherapy of Cancer (SITC). On the commercial side, Galon co-founded and served as Chief Scientific Officer (CSO) of HalioDx, an immuno-oncology diagnostic company acquired by Veracyte.
"For decades, I've believed that science and clinical progress must be driven by technological advances and approaches," said Dr. Galon. "Throughout my career, I've been involved with advanced imaging approaches that will improve patient outcomes. I am excited to support Elephas as they commercialize an exceptional technology that will impact how patients will be treated."
Elephas has pioneered an oncology platform that uses live fragments from a tumor biopsy to predict immunotherapy response. The Company's pan-solid tumor technology is designed to evaluate treatment effectiveness across indications, aiming to ensure patients get to the right treatment as soon as possible.
Dr. Galon is joining the SAB, which currently consists of the following leaders in oncology:
"We are grateful for the luminaries who have joined our advisory board to provide their expertise and help guide the future direction of Elephas," said Maneesh Arora, Elephas founder and CEO. "This group doesn't simply lend their name to our mission; they share a passion for improving the lives of cancer patients. The merging of clinical, academic, and international perspectives is invaluable as we work towards providing a solution that can help guide clinicians and enhance access to life-changing immunotherapies."
About Elephas
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle the massive oncology dilemma, Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the Elephas Live platform enables a real-time characterization of immune response. To learn more, visit www.elephas.com and follow us on LinkedIn.
SOURCE Elephas
Share this article